CDER Conversation on Disclosing Information About Drugs and Fostering CDER’s Transparency Efforts - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. CDER Conversation: Disclosing Information About Drugs and Fostering CDER's Transparency Efforts  CDER's Office of Regulatory Policy's (ORP) Division of Information Disclosure Policy (DIDP) works to make CDER materials available to the public, all while adhering to relevant statutes, such as the Freedom of Information Act (FOIA), and other applicable disclosure laws. DIDP Deputy Director Darshini Satchi, JD, discusses how the division develops and implements CDER's disclosure activities, including proactively releasing content related to drug approvals and responding to external requests for information. Learn More This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA